|
Topic
Search
by Agent
|
Description |
Trial
Search |
Monoclonal
antibodies (Mab)
Mabs binds to molecules (antigens, receptors) on
target cells |
Rituxan
(Rituximab/ MabThera)
targets CD20 |
APPROVED
for CD20 lymphomas See Rituxan
Indication: Lymphoma/CLL expressing cd20 (APPROVED)
Rituxan (formerly C2B8) is an antibody that may induce killing of b-cells - malignant
and normal by inducing self killing, or by flagging the cells for attack
by the immune system
See Rituxan
|
ClinicalTrials.gov
(new uses) |
| Next
Generation anti-cd20 Mabs |
AAME-133v
(LY 2469298)
targets CD20
|
Indication: Lymphomas, b-cell (expressing cd20)
AME-133v
is hypothesized to result in an anti-CD20 therapy with greater potency and efficacy in all patients, but
particularly in genetically defined subpopulations that respond poorly to rituximab
(Rituxan) because they express a low
affinity version of the Fc receptor on their immune effector cells. A monoclonal antibody that has
increased binding for this receptor should be more effective in stimulating effector cell killing and thus
improve response to the antibody. This study is designed to provide evidence of the safety and a preliminary
understanding of the efficacy of AME 133v
|
ClinicalTrials.gov |
GA-101 type II antibody
targets CD20 |
Indication: Lymphomas, b-cell (expressing cd20)
Compared to existing CD20 antibodies GA101
represents a novel, third generation antibody with significantly
enhanced efficacy in a variety of in vitro and in vivo
preclinical models. GA101 constitutes the first type II CD20
antibody successfully engineered for increased ADCC. Based on
these data, GA101 is a promising therapeutic antibody candidate
for the treatment of B-cell malignancies.
ASH
2007
|
New |
HuMax-CD20
(ofatumumab)
targets CD20 |
Indication: Lymphoma/CLL, b-cell expressing cd20
(HuMax-CD20™) is a fully human, high-affinity antibody
targeted at the CD20 molecule in the cell membrane of B-cells.
Also see Report
on Clinical responses Feb 2008
|
ClinicalTrials.gov |
Immu-106
Ha20
(Veltuzumab)
targets CD20
|
Indication: Lymphomas, b-cell (expressing cd20)
"A [humanized anti-cd20] monoclonal antibody that is being
studied in the treatment of refractory B-cell non-Hodgkin's
lymphoma. Monoclonal antibodies are made in the laboratory and
can locate and bind to cancer cells. IMMU-106 binds to the
protein CD20, which is found on B cells (a type of immune system
cell), and some types of lymphoma cells. Also called hA20 and
HCD20." Source
Data: Phase I/II
Results. - ASH
2006 |
ClinicalTrials.gov |
| ocrelizumab
targets CD20
|
Indication: Lymphomas, b-cell (expressing cd20)
|
New |
| PRO131921
targets CD20
|
Indication: Lymphomas, b-cell (expressing cd20)
|
ClinicalTrials.gov |
Other
Mabs
Return to top |
Anti-idiotype BCR antibody panel
Targets portion of immunoglobulin |
Indication: lymphoma, not yet specified
|
Preclinical |
anti-CD45
antibody
(PD7/26/16 and 2B11)
targets CD45 |
Indication: Lymphomas, b-cell (expressing cd45)
|
ClinicalTrials.gov |
anti-cd74
antibody
(Milatuzumab)
targets CD74
|
"CD74:
a new candidate target for the immunotherapy of B-cell
neoplasms."
Immunomedics Patents Internalizing
Anti-CD74 Antibodies Reuters |
ClinicalTrials.gov |
| anti-MHC
II antibody |
Indication: lymphoma, not yet specified
|
Preclinical |
Campath
(alemtuzumab)
targets CD52
|
APPROVED for
CLL
Indication: Lymphomas: CLL
"A humanized monoclonal antibody directed against the
CD52 antigen with promising therapeutic effects in patients with
small cell lymphocytic non-Hodgkin's lymphomas (NHL) of B- and
T-cell type."
|
ClinicalTrials.gov |
CMC-544
targets CD22 |
Indication: Lymphoma, b-cell - cd22 positive
CMC-544 is a CD22-targeted immunoconjugate of calicheamicin
and exerts a potent cytotoxic effect against CD22+
B-cell lymphoma [in a mouse model]. Source |
ClinicalTrials.gov |
CT-011
antibody
targets B7 family-associated protein, |
Indication: Lymphomas
"CT-011, a humanized monoclonal antibody that is
directed against a B7 family-associated protein, was previously
shown to efficiently elicit anti-cancer immune response against
a wide range of murine and human tumors (Hardy et al PNAS
94:5756-5760, 1997). Its interaction with both NK cells and
CD4+CD45+RO T cells culminates in NK- and T- cell dependent
immune responses. CT-011 target-antigen operates through the
PI3K pathway to extend the survival of effector/memory T cells
and to promote the generation of tumor-specific memory T
cells." http://www.haematologica.org/
|
ClinicalTrials.gov |
Epratuzumab
targets CD22 |
Indication: Lymphoma, cd22 positive
Epratuzumab is an anti-CD22 humanized monoclonal antibody |
ClinicalTrials.gov |
Hu-Max-CD4
targets CD4 |
Indication: Lymphoma, T-cell
(Zanolimumab) HuMax-CD4® is a human antibody being developed
under an agreement with Serono and is currently in Phase III
development for cutaneous T-cell lymphoma (CTCL) and in Phase II
for non-cutaneous T-cell lymphoma. These types of lymphomas
express the CD4 receptor, which can be targeted by Genmab’s
HuMax-CD4 antibody. Source
|
ClinicalTrials.gov |
Idec-114
targets CD80 |
Indication: Lymphoma
(Galiximab, Anti-CD80 Monoclonal Antibody) |
ClinicalTrials.gov |
lumiliximab
targets CD23 |
Indication: Lymphomas (expressing cd23)
CD23, the low-affinity immunoglobulin (Ig)E receptor (FcepsilonRII),
is widely distributed on the surface of various human cells.
CD23 mediates numerous IgE-related immune responses (including
allergen focusing) by enhancing IgE antigen complex
presentation, regulating IgE synthesis, influencing cell
differentiation and growth of both B- and T-cells, and
stimulating production of pro-inflammatory mediators from
monocytes/macrophages, eosinophils, and even airway smooth
muscle cells. Source
| Background
article |
ClinicalTrials.gov |
SGN 30
targets CD30 |
Indication: Lymphoma expressing cd30
(Anti-CD30 Monoclonal Antibody) is a
monoclonal antibody that targets the CD30 antigen, which is
expressed on hematologic malignancies including Hodgkin's
disease and some T-cell non-Hodgkin's lymphomas. Seattle
Genetics is conducting ongoing phase II clinical trials of
SGN-30 as a single agent in systemic ALCL and cutaneous ALCL."
Press
release
|
ClinicalTrials.gov |
Siplizumab
(MEDI-507)
targets CD2 |
Indication: Lymphoma expressing cd2
Siplizumab is a development-stage monoclonal
antibody (MAb) being evaluated in adults with CD2-positive
lymphoma or leukemia. Partial disease remissions for some study
participants were among the data presented by the National
Cancer Institute (NCI) during a poster session at the 41st
American Society of Clinical Oncology (ASCO) |
ClinicalTrials.gov |
Mabs
Coupled with Toxins or Chemo
Return to top |
BL22
immunotoxin
targets CD22 |
Indication: Lymphomas, b-cell (expressing cd22)
BL22 immunotoxin can find tumor cells that express cd22
[mature b-cells] and
kill them. The specificity of the agent may be a reason that it is open
to patients with relatively low bone marrow function
(low blood counts). Complete responses in Hairy cell
leukemia have been encouraging. |
ClinicalTrials.gov |
CAT-8015
immunotoxin
targets CD22 |
Indication: Lymphomas
CAT-8015 is an optimized
version of CAT-3888 with increased affinity for CD22.
CD22 is a cell surface receptor expressed in a wide variety of
B-cell malignancies. The anti-CD22 immunotoxin CAT-8015
comprises a dsFv that targets the CD22 receptor, fused with a
specifically engineered toxin molecule that minimizes
non-targeted toxicity, resulting in a highly specific, highly
potent therapeutic molecule. The molecule acts by releasing the
toxin intracellularly, after the whole immunotoxin has been
internalised via the CD22 receptor.
" |
ClinicalTrials.gov |
LMB-2
immunotoxin
targets
IL-2 receptor |
Indication: Lymphomas, b-cell (expressing
cd45)
|
ClinicalTrials.gov |
Mono-dgA-RFB4
targets CD22 |
Indication: Lymphomas, b-cell
Scant background information so far; one trial
|
ClinicalTrials.gov |
Ontak
(denileukin diftitox)
Denileukin
diftitox (Ontak) is IL-2/diphtheria toxin fusion protein.
targets
IL-2 receptors
|
Indication: Lymphoma (APPROVED for t-cell lymphomas)
(DAB389 IL-2)
TOPIC SEARCH: Mechanisms PubMed
Outcome ASCO
| Medscape |
PubMed
Safety ASCO
| PubMed
Denileukin diftitox (Ontak) is
IL-2/diphtheria toxin fusion protein. The IL-2 portion of the
molecule targets the lymphoma cells by binding to the IL-2
receptor on the plasma membrane, and upon endocytosis, the
diphtheria toxin is delivered to the lymphoma cells. Common side
effects are nausea and vomiting, fever and flu-like symptoms.
Other significant side effects include the cytokine release
syndrome and vascular leak syndrome.
351
Acute complaints reported on the first day of treatment include
back pain, shortness of breath, flushing, rash, chest pain,
difficulty swallowing, dizziness and fainting. Only 2% of
patients experienced severe reactions. Slowing or terminating
the infusion and administering antihistamines, corticosteroids
and epinephrine can relieve these reactions. Prophylactic
treatment with systemic corticosteroids is recommended - http://www.ncbi.nlm.nih.gov/
Case report on safety:
Vision loss following denileukin diftitox treatment: a
case report of possible posterior ischemic optic neuropathy.
Leuk Lymphoma. 2007 Apr;48(4):808-11. No abstract available. PMID:
17454642
Case report on safety:
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
Am J Hematol. 2008 Feb 15; PMID: 18335564
|
ClinicalTrials.gov |
Bispecific
Mabs
binds two antigens on target cells
Return to top |
| 4G7xH22 |
Indication: In Patients
With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic
Lymphocytic Leukemia (CLL)
Intravenous Bispecific
Antibody (4G7XH22) |
ClinicalTrials.gov |
BiTE
(MT103)
targets CD19 |
Indication: Lymphomas, b-cell (expressing cd19)
"MT103 (also known as MEDI-538) is a recombinant
single-chain bispecific antibody derivative out of Micromet’sBiTE®
platform targeting the CD19 antigen, which is uniquely expressed
on B cells." Source
PDF
Also see: News
item on clinical responses Feb 2008
|
ClinicalTrials.gov |
Radio-labeled
monoclonal antibodies
(Radioimmunotherapy - RIT)
Return to top |
|
Fractionated radioimmunotherapy
targets CD22
|
Indication: Lymphomas expressing cd20
"radioimmunotherapy (RAIT) using epratuzumab to deliver
toxic radiation directly to lymphoma cells in small fractions."
Source |
ClinicalTrials.gov |
Bexxar
(tositumomab)
targets CD20 |
APPROVED
for relapsed indolent lymphoma. See Bexxar
Indication: Lymphomas, b-cell (expressing cd20)
(iodine I 131 tositumomab) |
ClinicalTrials.gov
(new uses) |
Zevalin
targets CD20 |
(APPROVED for relapsed cd20
lymphoma) See Zevalin
Indication: b-cell Lymphoma |
ClinicalTrials.gov
(new uses) |
Inhibitors
of Apoptosis
Apoptosis: programmed cell death - a normal process by which the body rids itself of old,
unneeded, or damaged cells. This mechanism is similar to how too much sun can
trigger exposed skin cells to peel.
Return to top
|
ABT-263
targets inhibibitors of apoptosis |
Indication: Lymphoma
"ABT-263 is an orally bioavailable small molecule inhibitor
of Bcl-2 family proteins with a Ki of < 1
nM against Bcl-2, Bcl-XL, and Bcl-w. Non-Hodgkin s
B-cell lymphomas represent clinically relevant disease targets
for this molecule due, in part, to strong expression of Bcl-2
often associated with various types of NHL (frequently involving
a t(14;18) translocation including the Bcl-2 locus). ABT-263
exhibits sub-micromolar in vitro activity against a variety of
NHL cell lines. DoHH-2 and WSU-DLCL2 are two B-cell
NHL lines harboring the t(14;18) translocation that exhibit
differential in vitro sensitivity to ABT-263. Granta-519 is a
mantle cell lymphoma line with the characteristic
t(11;14)(q13:q32) translocation resulting in overexpression of
cyclin D1. ABT-263 has an EC50 of approximately 150
nM in the Granta-519 cell line." Source |
ClinicalTrials.gov |
AP1903
targets apoptosis |
Indication: MDS
"The
therapy involves infusing donor T lymphocytes engineered with a
gene encoding an inactive apoptosis protein."
|
ClinicalTrials.gov
(none listed
as of 12/06) |
APO866
targets apoptosis |
Indication: t-cell lymphomas
"APO866 has a novel mechanism of action that
selectively depletes the cell’s energy, leading to apoptotic
cell death and also exerting anti-angiogenic
activity.
Apoxis is also exploring the
use of APO866 in combination with other chemotherapeutics and
also as a radiosensitizer.
In immunology, APO866 exerts
inhibitory effect on T-cells offering the potential as a
treatment for autoimmune diseases "
- Source
|
ClinicalTrials.gov
|
AT-101
targets
BCL-2 family inhibitors of
apoptosis |
Indication: Lymphomas
Pan-Bcl-2 Inhibitor
Source
Safety article: ascentatherapeutics.com
.pdf
... AT-101 induces apoptosis in primary leukemia cells from patients with CLL. This effect is concentration
dependent (IC50= 2μM) and it is independent of the expression of prognostic factors such as ZAP-70 or IgVH gene mutational status in
the leukemia cells.
- AT-101 seems to have stronger pan-specific binding affinity for Bcl-2 family proteins than racemic gossypol, in particular to Mcl-1 and
Bcl-XL. "
Background
article PDF |
ClinicalTrials.gov
|
New:
Fenretinide
(4-HPR)
induces
apoptosis
|
Indication: Lymphoma/CLL
... Combinations of 4HPR (an analogue of
vitamin A) + rituximab exceeded
the predicted 50% additive rate of disease control from each
agent alone (P =.038). Administering 4HPR and rituximab to mice
with established tumors induced complete responses (CRs) in 80%
of animals compared with 20% to 40% CRs using either agent alone
(P =.07), resulting in significantly improved survival..
- Source
| See also CLLtopics
overview |
ClinicalTrials.gov |
GMX1777
inhibit
bcl-2 |
Indication: Lymphoma/CLL
... aimed at the key mechanisms of resistance
to apoptosis, which play a central role in cancer cell survival.
These include overexpression of anti-apoptotic Bcl-2 proteins
and defects in the p53 pathway. ... GMX1777,
a small molecule pro-apoptotic agent scheduled to enter the
clinic in Q4 2006 represents Gemin X's second program.
- Source |
ClinicalTrials.gov |
GX15-070MS
targets
bcl-2 (apoptosis) |
Indication: Lymphoma/CLL/MCL
The inhibition of the antiapoptotic Bcl-2
proteins is an attractive strategy for either restoring normal
apoptotic process in cancer cells or making these cells more
susceptible to conventional chemotherapy. - Source |
ClinicalTrials.gov |
HA14-1
targets inhibitors of
apoptosis |
Indication: Lymphomas/CLL
HA14-1, a small molecule Bcl-2
antagonist, induces apoptosis and modulates action of selected
anticancer drugs in follicular lymphoma B cells. |
preclinical |
YM155
targets survivin - inhibitor of apoptosis |
Indication: Lymphomas
A novel proapoptotic agent with potential antineoplastic
activity. Survivin inhibitor YM155 selectively inhibits survivin
expression in tumor cells, resulting in inhibition of survivin
antiapoptotic activity (via the extrinsic or intrinsic apoptotic
pathways) and tumor cell apoptosis.
Survivin, a member of the inhibitor of apoptosis (IAP) gene
family, is
expressed during embryonal development and is absent in most
normal, terminally differentiated tissues; upregulated in a
variety of human cancers, its expression in tumors is associated
with a more aggressive phenotype, shorter survival times, and a
decreased response to chemotherapy.
http://www.cancer.
gov/Templates/
drugdictionary.
aspx?CdrID=
476771
|
ClinicalTrials.gov |
Immunotherapy
Activating the immune system to fight cancer
Also see Immunotherapy
Return to top
|
1018 ISS
immune modulation |
Indication: Lymphoma, follicular
"CpG oligodeoxynucleotides (CpG-ODNs)
affect innate and adaptive immune responses, including antigen
presentation, costimulatory molecule expression, dendritic cell
maturation, and induction of cytokines enhancing
antibody-dependent cell-mediated cytotoxicity (ADCC)" Source |
ClinicalTrials.gov |
Actimmune
immunotherapy |
Indication: B-cell lymphoma
intra-tumoral injections of an adenoviral vector construct
containing the human interferon gamma gene |
ClinicalTrials.gov |
AD-Ifng
(TG1042)
viral vector |
Indication: Lymphoma, cutaneous b- or t-cell
TG1042 is a third-generation,
nonreplicating human adenovirus vector containing a human IFN-gamma
cDNA insert." Source
Data: http://www.biovalley.com/images_messages/image2/749.pdf
|
ClinicalTrials.gov |
CPG-7909
immune adjuvant |
CPG-7909 (PF-3512676, ProMune®):
toll-like receptor-9 agonist in cancer therapy expertopin.com
Stimulation of toll-like receptor (TLR)9 activates human
plasmacytoid dendritic cells and B cells, and induces potent
innate immune responses in preclinical tumor models and in
patients. CpG oligodeoxynucleotides (ODNs) are TLR9 agonists
that show promising results as vaccine adjuvants and in the
treatment of cancers, infections, asthma and allergy. |
ClinicalTrials.gov |
gm-CSF
(Leukine)
immune modulating |
Indication: Lymphoma
LEUKINE® (sargramostim) is a recombinant
human granulocyte-macrophage colony-stimulating factor.
Investigational use as a adjuvant to enhance Mab and vaccine
therapy.
|
ClinicalTrials.gov |
Idiotype
vaccine
(FavId)
adaptive immunotherapy |
Indication: Lymphoma expressing idiotype
Idiotype vaccine starts with
a biopsy (sometimes blood) to acquire fresh tissue. The idiotype
protein is isolated from the tumor. To make the vaccine more
visible to the immune system (immunogenic), the Idiotype is
bound with an adjuvant that is known to stimulate an immune
response; in this vaccine, KLH. |
ClinicalTrials.gov |
Idiotype
vaccine
(Myvax)
adaptive immunotherapy |
Indication: Lymphoma/CLL expressing idiotype
Idiotype vaccine starts with
a biopsy (sometimes blood) to acquire fresh tissue. The idiotype
protein is isolated from the tumor. To make the vaccine more
visible to the immune system (immunogenic), the Idiotype is
bound with an adjuvant that is known to stimulate an immune
response; in this vaccine, KLH. |
ClinicalTrials.gov |
Idiotype
vaccine
(BiovaxID)
adaptive immunotherapy |
Indication: Lymphoma expressing idiotype
Idiotype vaccine starts with
a biopsy (sometimes blood) to acquire fresh tissue. The idiotype
protein is isolated from the tumor. To make the vaccine more
visible to the immune system (immunogenic), the Idiotype is
bound with an adjuvant that is known to stimulate an immune
response; in this vaccine, KLH.
|
ClinicalTrials.gov |
Idiotype
dendritic vaccine
adaptive immunotherapy |
Indication: Lymphoma
Tumor-specific clonal immunoglobulin expressed by B-cell
lymphomas (idiotype [Id]) can serve as a target for active
immunotherapy. We have previously described the vaccination of 4
patients with follicular lymphoma using dendritic cells (DCs)
pulsed with tumor-derived Id protein - Source
|
ClinicalTrials.gov |
Interleukin
2 (Aldesleukin)
immune modulating |
Indication: Lymphoma
"an interleukin,
or hormone
of the immune
system that is instrumental in the body's natural response
to microbial infection and in discriminating between foreign (nonself)
and self. IL-2 mediates its effects by binding to IL-2
receptors, which are expressed by lymphocytes,
the cells that are responsible for immunity." Wikipedia |
ClinicalTrials.gov |
Interleukin
21 (IL-21)
immune modulating |
Indication: Lymphoma
...
"IL-21 is a cytokine that can promote the anti-tumor
responses of the innate and adaptive immune system. Mice treated
with IL-21 reject tumor cells more efficiently, and a higher
percentage of mice remain tumor-free compared with untreated
controls. In this study, we demonstrate that in certain tumor
models IL-21-enhanced tumor rejection is NKG2D dependent. When
engagement of the NKG2D receptor was prevented, either due to
the lack of ligand expression on the tumor cells or due to
direct blocking with anti-NKG2D mAb treatment, the protective
effects of IL-21 treatment were abrogated or substantially
diminished. Specifically, IL-21 only demonstrated a therapeutic
effect in mice challenged with a retinoic acid early
inducible-1delta-bearing lymphoma but not in mice bearing
parental RMA tumors lacking NKG2D ligands. Source. |
ClinicalTrials.gov |
Lenalidomide
(CC-5013, Revlimid)
immune modulation/
anti-angiogenesis |
(APPROVED for
MDS
Indication: Lymphoma/CLL
The analogues of thalidomide, CC-5013 (lenalidomide,
Revlimid) and CC-4047 (Actimid) are more potent regulators of
cellular immune and cytokine response while lacking some of the
dose limiting side effects of the parent compound, such as
neurologic toxicity. Source
Mechanisms PubMed
Outcome ASCO
| Medscape |
PubMed
Safety ASCO
| PubMed
|
ClinicalTrials.gov |
MDX-010
targets CTLA-4 -
immune modulating |
Indication: Lymphomas
|
ClinicalTrials.gov |
Proleukin
(aldesleukin)
immune modulating |
Indication: Lymphoma
Recombinant interleukin-2 (IL-2)
|
ClinicalTrials.gov |
Intercellular Cancer Pathways
(Molecular targets)
Targets processes within the cell that lead
to malignant behavior
Return to top
|
| Affinitak
targets
protein
kinase C-alpha
|
Indication: lymphoma, not yet specified
"ISIS 3521 (Affinitak™, LY900003 / (ISIS3521)) is a phosphorothioate anti-sense oligonucleotide
compound that selectively inhibits the production of protein
kinase C-alpha."
|
ClinicalTrials.gov
(none listed
as of 12/06) |
AVI-4126
targets
MYC oncogene |
Indication: Lymphomas
Novel anti-sense "The inactivation of MYC may be a specific
and effective treatment for these tumors. To address for this
possibility, I have developed a novel mouse model system to
conditionally regulate MYC expression in mouse lymphocytes.
Previously, I have used this model system to demonstrate that
the inactivation of MYC can be sufficient to cause the sustained
regression of cancers." Source
|
ClinicalTrials.gov
(none listed
as of 12/06) |
BAY 43-9006
(Sorafenib/Nexavar)
targets
RAF kinase |
Indication: Lymphomas
NBAY 43-9006 is a "targeted drug" specifically
engineered to inhibit something called the RAF kinase within the
cancer cells. RAF in turn is part of the RAS oncogene pathway.
RAS is a gene which drives cell division and is overexpressed in
many cancers, including RCC. Source
|
ClinicalTrials.gov |
BCX-1777
(Forodesine)
targets
PNP enzyme
|
Indication: Lymphoma, t-cell cutaneous
(Forodesine) PNP-inhibitor. May
stop the growth of cancer cells by blocking the enzymes
necessary for cancer cell growth.
PURPOSE:
Phase I/II trial to study the effectiveness BCX-1777 in treating
patients who have refractory cutaneous T-cell lymphoma.
 |
ASH:
Forodesine HCl active single oral agent for advanced
refractory CTCL abstracts2view.com
|
|
ClinicalTrials.gov |
BMS-247550
targets
tubulin |
Indication: Lymphomas
The epothilone B analogs are non-taxane tubulin stabilizing
compounds that are active in taxane-resistant and -sensitive
preclinical models. BMS-247550 is a semi-synthetic epothilone B
analog that has shown activity in phase I trials against the
non-Hodgkin’s lymphomas (NHL). Source |
ClinicalTrials.gov |
CCI-779
targets
mTOR |
"temsirolimus (CCI-779), an inhibitor of mTOR kinase used
as single agent achieved an overall response rate of 38% in
relapsed MCL patients. Source
Single-agent CCI-779 has substantial anti-tumor activity in relapsed MCL. This study demonstrates that agents, which selectively target cellular pathways dysregulated in MCL cells can produce therapeutic benefit. The high response rate warrants further studies of this agent in MCL, but the high incidence of hematologic toxicity suggests that a lower dose should be explored. CCI-779 at 25mg is currently being evaluated in MCL through an NCCTG trial
Abstract #129 appears in Blood, Volume 104, issue 11, November 16, 2004 "
|
ClinicalTrials.gov |
CDDO
targets
PPAR gamma |
Indication: Lymphomas:
"Ligands for the transcription factor peroxisome
proliferator-activated receptor gamma (PPAR gamma) are emerging
as a new class of antitumor agents. Herein, we investigated the
triterpenoid CDDO, a PPAR gamma ligand, for its potential as an
anticancer agent on human diffuse large B-cell lymphoma (DLBCL)
cells. Source |
ClinicalTrials.gov |
CS-1008
targets
TRAIL receptor |
CS-1008 (humanized anti-DR5
antibody) |
ClinicalTrials.gov |
Enzastaurin
targets
protein kinase C-beta |
Indication: Lymphomas
Orally administered protein kinase C-beta (PKCbeta) inhibitor
Source
Also see NEWS: http://www.docguide.com/news/ |
ClinicalTrials.gov |
Everolimus
targets
FK binding protein, mTOR
Background |
Indication: Lymphoma, MCL Study
NEWS:
Everolimus Active in Relapsed Aggressive
Non-Hodgkin’s Lymphoma http://clinicaloptions.com
 | Target of rapamycin (mTOR) inhibitors in NHL |
 | Overall response rate: 32% |
 | Treatment well tolerated over extended
duration
 | Interim data support further
investigation |
|
|
ClinicalTrials.gov |
flavopiridol
inhibits
cyclin-dependent kinase (CDK)4-cyclin D1 complex |
Indication: Lymphomas, b-cell
|